Agnes Cser, Rapporteur of the European Economic and Social Committee’s exploratory opinion “Leaving No One Behind: European Commitment to Tackling Rare Diseases”

Dr Agnes Cser is a barrister and healthcare manager. Since joining the European Economic and Social Committee (EESC) in 2004, she has made exceptional contributions to the work of EESC and was a founding member of the Ethical Committee. In 2009, she became the first EESC rapporteur to present an opinion on rare diseases, the ‘Proposal for a Council Recommendation on a European action in the field of rare diseases’, and later supported the 2022 opinion ‘Ensuring strong European solidarity for rare disease patients’.
More recently she served as rapporteur of the exploratory opinion ‘Leaving No One Behind: European Commitment to Tackling Rare Diseases’. 

Through her tireless leadership, Dr Cser has amplified the voices of people living with rare diseases, their families and civil society, creating lasting impact across Europe.

Anna Rath, Orphanet Director

Ana Rath is a medical doctor with a background in general surgery and a Masters degree in Philosophy. She oriented her career to medical information and terminologies in 1997 and joined Orphanet (www.orpha.net) in 2005, where she was Manager of the Orphanet Encyclopaedia, then Scientific Director, and Director of Orphanet and Coordinator of the Orphanet network since 2014. Ana acted as the coordinator of RD-ACTION Joint Action from 2015 to 2018 and of the IRDiRC’s Scientific secretariat until 2017. She chairs the Orphanet Rare Disease Ontology (ORDO), and was member of the WHO’s ICD11 Revision Steering Committee. 

She coordinates projects on implementation of RD codification in EU member states (RD-CODE, OD4RD). She contributes to JARDIN Joint Action on RD data standardisation and co-chairs the ERDERA’s Data Service Hub on data and resources ecosystem for RD research in Europe. She is Commissioner at the Lancet Commission for Rare Diseases.

Antoni Montserrat Moliner, Vice-President, ALAN-Maladies Rares, Luxembourg

Antoni Montserrat Moliner worked in Eurostat, as Policy Officer in health statistics (1990-2003) and in the Public Health Directorate of the European Commission as Senior Expert on the policies on rare diseases and cancer (2004-2017) where he initiated the Commission’s Communication, the Council’s Recommendation on rare diseases as well as their implementation and some of the Joint Actions in different areas (rare cancers, national plans, registers, ERN, technical assistance to national plans/strategies on rare diseases, etc.). He is always Active Senior on Public Health for the European Commission.
He joined ALAN Maladies Rares’s Board of Directors in Luxembourg in 2018 becoming Vice-president in 2024. He was appointed as member of the Luxembourgish Steering Committee of the National Plan for Rare Diseases (CNMR) and Supervisor for the creation of the Luxembourg register of RD. He became President of the CNMR in 2026.  He’s also member of the EURORDIS (Rare Diseases Europe) Woking Group on Newborn Screening and active member of his CNA (Council of National Alliances).

Ellen Crushell, Deputy Chief Medical Officer, Department of Health, Ireland

Professor Ellen Crushell is a Deputy Chief Medical Officer at Ireland’s Department of Health. She is also a consultant paediatrician specialising in inherited metabolic disorders at Children’s Health Ireland. She previously served as Ireland’s National Clinical Lead for Paediatrics and Neonatology and as Dean of the Faculty of Paediatrics at the Royal College of Physicians of Ireland. She has represented Ireland in the European Academy of Paediatrics and EPA/UNEPSA and is Clinical Professor at University College Dublin. Her interests include child health and wellbeing, rare diseases and the social determinants of health.

Jean Saslawsky, Chief Executive Officer, EURORDIS-Rare Diseases Europe

Jean Saslawsky is Chief Executive Officer of EURORDIS-Rare Diseases Europe, the independent voice representing people living with rare diseases across Europe. He joined EURORDIS in June 2026, bringing more than 25 years of leadership experience across the health, humanitarian and social impact sectors.
Before joining EURORDIS, Jean served as Director of Programs, Operations and Advocacy at CARE France, where he led international operations across 50 countries and advocacy engagement with French and European decision-makers. He previously served as Secretary General of the international network of Médecins du Monde (Doctors of the World), coordinating 15 national organisations across Europe, the Americas and Asia and helping to develop the network’s first global strategy.
Jean has also served as Director General of Fondation La France s’engage, supporting social innovation and strengthening partnerships with companies and philanthropic organisations.
Throughout his career, Jean has worked at the intersection of health, international cooperation, advocacy and organisational development. He began his career in humanitarian field operations, including assignments in Bosnia and Georgia, experiences that shaped his long-standing commitment to public service and solidarity.

Seán Byrne, Associate Director, Science Policy & Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Seán Byrne is the Associate Director of Science Policy & Regulatory Affairs at EFPIA and has been with the organization since 2025. He previously served as a Senior Manager in Legal & Regulatory Affairs at EUCOPE and worked as a Policy Adviser for the American Chamber of Commerce to the European Union. Additionally, Seán held roles such as Senior Account Manager at Rud Pedersen Public Affairs and Healthcare Biotechnology Manager at EuropaBio. With a Ph.D. in law focused on scientific and technological advancement, he also posesses a background in medical law and bioethics.

Susan O’Connell, Consultant Paediatric Endocrinologist, Children’s Health Ireland; Incoming Paediatric Chair and Vice-Coordinator Endo-ERN

Professor Susan O’Connell is a Consultant Paediatric Endocrinologist at Children’s Health
Ireland (CHI) and Clinical Associate Professor at RCSI University of Medicine and Health
Sciences. She graduated from University College Dublin (UCD), completed her doctorate at
Trinity College Dublin (TCD), and undertook an international fellowship in Western Australia.
Since returning to Ireland in 2012, she has been actively involved in advancing rare disease care,
research and policy at national and European levels. She was a member of Ireland’s National
Clinical Programme for Rare Diseases from 2013 and chaired the working group responsible for
the HSE’s Model of Care for Transition from Paediatric to Adult Healthcare Providers in Rare
Diseases (2018).
Susan has served as Paediatric Lead for Ireland within the European Reference Network on Rare
Endocrine Conditions (ENDO-ERN) since 2022 and was recently elected Paediatric Chair of
ENDO-ERN, a role she will formally assume in April 2027.
Her clinical and research interests include improving transition of care, international rare disease
registries and collaborative research. She is a co-investigator in the HRB/EU-funded Rare
Disease Research Catalyst (RD CAT), supporting Ireland’s rare disease research capacity and
engagement with European initiatives, including the European Rare Diseases Research Alliance
(ERDERA).
Through her work within ENDO-ERN, she is committed to strengthening European
collaboration in rare disease research, education and training, and improving equitable access to
specialist expertise and innovative therapies. She recognises the central importance of
meaningful patient and public involvement in shaping research priorities, informing service
development and ensuring that advances in rare disease care reflect the needs and experiences of
patients and families.
She sees Ireland’s Presidency of the Council of the European Union as an important opportunity
to celebrate progress, showcase Ireland’s contribution and strengthen European partnerships,
bringing together clinicians, researchers, patients and patient organisations to translate shared
expertise and innovation into meaningful improvements in care and outcomes for people living
with rare diseases across Europe.